Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Vote In favor of Your Favored Kind Of Tea - 26 Famous Urban communities for Shopping on the planet
- 3See as Your #1: These Low-Sugar Food sources You Ought to Attempt
- 4Picking the Right Air Purifier for Your Home
- 5Figure out How to Upgrade Your Gold Speculation Portfolio: Vital Bits of knowledge and Strategies
- Drenched in Pixels: A Survey of \Vivid Interactivity Experience\ Game
- 'Sex and the City' star Kim Cattrall marries longtime partner Russell Thomas in intimate London wedding
- Illustrations Gained from a Crosscountry Excursion
- One lightly wounded after Iranian missile barrage targets northern Israel
- A throat bone settles it - Nanotyrannus was not a juvenile T. rex
- Understanding Preschool Projects: Cultivating Abilities and Advancement
- UK to hold fresh pork, other affected Spanish products at border amid African swine fever outbreak
- Amateur's Manual for Venture Strategies for Tenderfoots
- New York to require social media platforms to display mental health warnings
